6-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2025

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33^rd^ Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⊠ Form 40-F □

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT INDEX

Exhibit 99.1

XORTX THERAPEUTICS INC.

NOTICE OF CHANGE OF AUDITOR

PURSUANT TO SECTION 4.11 OF NATIONAL INSTRUMENT 51-102

Alberta Securities Commission

British Columbia Securities Commission

Ontario Securities Commission

Dear Sirs/Mesdames:

Re: Notice of Change of Auditor Pursuant to Section 4.11 of National Instrument 51-102

Notice is hereby given that Smythe LLP (the "Former Auditor") resigned as auditors of the Company effective January 16, 2025 and Davidson & Company LLP (the "Successor Auditor") has been appointed as auditors of XORTX Therapeutics Inc. (the "Company" or "XORTX"), effective January 16, 2025. The Audit Committee and the Board of Directors of XORTX considered and approved both the resignation of the Former Auditor and the appointment of the Successor Auditor as auditors of XORTX.

No modified opinion was expressed in the Former Auditor's report on any of the Company's financial statements relating to the period commencing at the beginning of the two most recently completed fiscal years and ending on December 31, 2023. The Former Auditor did not audit any financial statements of the Company subsequent to the fiscal year of the Company ended December 31, 2023.

In the opinion of the Company, prior to the resignation, and as at the date hereof, there were no reportable events, including disagreements, consultations, or unresolved issues as defined in National Instrument 51-102 - Continuous Disclosure Obligations, between the Former Auditor and the Company.

DATED at Vancouver, British Columbia this 16^th^ day of January, 2025.

BY ORDER OF THE BOARD OF DIRECTORS OF

XORTX THERAPEUTICS INC.

*signed "*MichaelBumby"

Michael Bumby

Chief Financial Officer

Exhibit 99.2

January 16, 2025 Private and Confidential Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission Dear Sirs/Mesdames: R E : XORTX T HERAPEUTICS I NC . ( THE “C OMPANY ”) C HANGE OF A UDITOR We are writing in accordance with Section 4.11(5)(a) of National Instrument 51 - 102 Continuous Disclosure Obligations (“NI 51 - 102”). We wish to confirm that we have read the Notice of Change of Auditor of the Company dated January 16, 2025 and that based on our current knowledge we are in agreement with the information contained in such Notice. Yours very truly, Chartered Professional Accountants

Exhibit 99.3

January 16, 2025 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission Dear Sirs/Mesdames: Re: XORTX Therapeutics Inc. (the "Company") Notice Pursuant to NI 51 - 102 - Change of Auditor As required by the National Instrument 51 - 102 and in connection with our proposed engagement as auditor of the Company, we have reviewed the information contained in the Company's Notice of Change of Auditor, dated January 16 , 2025 (the “Notice”), and, based on our knowledge of such information at this time, we agree with the information contained in the Notice pertaining to our firm . Yours very truly, DAVIDSON & COMPANY LLP Chartered Professional Accountants cc: TSX Venture Exchange